Dabigatran etexilate: The first oral anticoagulant available in the united states since warfarin

Cardiology in Review

Volumn 19, Issue 3, 2011, Pages 154-161

  Tran, Arlene ^a   Cheng Lai, Angela ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

dabigatran etexilate; direct thrombin inhibitor; oral anticoagulant

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; DABIGATRAN ETEXILATE; ENOXAPARIN; KETOCONAZOLE; QUINIDINE; VERAPAMIL; WARFARIN;

ARTICLE; BLEEDING; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DYSPEPSIA; EMBOLISM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; STROKE; UNITED STATES; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; HUMANS; PYRIDINES; SAFETY; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 79955073819     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3182137758     Document Type: Article

References (24)

1. Ma TK, Yan BP, Lam YY. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther. 2011; 129:185-194.
2. Hrebickova L, Nawarskas JJ, Anderson JR. Ximelagatran: a new oral anticoagulant. Heart Dis. 2003;5:397-408. (Pubitemid 37521685)
3. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28:1354-1373.
4. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15:9S-16S.
5. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics, and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303. (Pubitemid 47283865)
6. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpreation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
7. Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008;68:1699-1709.
8. Pradaxa-package insert-. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2010.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
10. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. As analysis of patients undergoing cardioversion. Circulation. 2011;123:131-136.
11. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol. 2007;100:1419-1426. (Pubitemid 47576022)
12. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2:1573-1580. (Pubitemid 40186173)
13. Erikkson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-111. (Pubitemid 41647122)
14. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370: 949-956. (Pubitemid 47393577)
15. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185. (Pubitemid 47617868)
16. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24: 1-9.
17. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
18. Gage BM. Can we rely on RE-LY? N Engl J Med. 2009;361:1200-1202.
19. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. Chest. 2008;133(suppl 6):381S- 453S.
20. Dabigatran etexilate (Pradaxa)-a new oral anticoagulant. Med Lett Drugs Ther. 2010;52:89-90.
21. Abdelhafiz AH, Wheeldon NM. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. Am J Geriatr Pharmacother. 2003;1:53-60. (Pubitemid 40410975)
22. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother. 2005; 39:446-451. (Pubitemid 40276873)
23. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47: 285-295. (Pubitemid 351508116)
24. RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed RE-LY trial-online-. ClinicalTrials.gov; 2000. Available at: http://clinicaltrials.gov/ct2/show/ NCT00808067?term-dabigatran&rank-5. Cited January2,2011.